Biomatters
Biomatters (Geneious) is a New Zealand-based bioinformatics software company, founded in 2003 and part of Dotmatics since 2022, providing subscription-based Geneious Prime desktop and Geneious Biologics cloud platforms for molecular biology, sequence analysis, and antibody discovery to universities, research institutes, and pharmaceutical companies across 125 countries.
- Company typePrivate
- Founded2003
- HeadquartersAuckland, New Zealand
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Biomatters does
Biomatters Ltd., operating under the Geneious brand, is a New Zealand-headquartered bioinformatics software company founded in 2003 and currently operating as a subsidiary of Dotmatics following its 2022 acquisition. The company develops and distributes Geneious Prime, a desktop suite of molecular biology and sequence analysis tools covering DNA/RNA analysis, sequence assembly, phylogenetics, molecular cloning, primer design, CRISPR workflows, NGS visualization, and NCBI/BLAST integration. Geneious Biologics, its cloud-based product, provides antibody screening, clustering, and filtering for antibody discovery pipelines. A free tier, Geneious Biologics Starter, supports a product-led growth motion alongside direct self-serve sales on the website.
Revenue is generated primarily through subscription licensing: annual and multi-year Geneious Prime subscriptions, Geneious Biologics cloud subscriptions, enterprise site licenses for pharmaceutical and large research institutions, and à-la-carte plugins. Distribution is multimodal — direct website sales for individual researchers and small labs, enterprise field sales for large pharma accounts (Novartis, Bristol-Myers Squibb, Genentech, BioMarin, Abcam, Sangamo Therapeutics), and Dotmatics platform cross-sell for broader R&D software procurement. The company serves two primary verticals: universities and research institutions (Stanford, University of Tokyo, Rutgers, University of Freiburg, Karolinska Institute) and pharmaceutical/biotechnology companies, with 4,000+ customer organizations across 125 countries.
Technology is delivered through a desktop application with plugin extensibility, an API and CLI for developers, and a cloud-hosted biologics platform. The Geneious platform sits within the Dotmatics scientific R&D software portfolio alongside GraphPad Prism, SnapGene, OMIQ, Protein Metrics, and the Luma Scientific Intelligence Platform. Specific revenue, headcount trend, and AI capability disclosures are limited; the company's AI positioning currently centers on the parent-level Luma offering rather than Biomatters-developed models.
Biomatters firmographics
Firmographics- Name
- Biomatters
- Legal name
- Biomatters Ltd.
- Website
- https://biomatters.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Biomatters (Geneious) is a New Zealand-based bioinformatics software company, founded in 2003 and part of Dotmatics since 2022, providing subscription-based Geneious Prime desktop and Geneious Biologics cloud platforms for molecular biology, sequence analysis, and antibody discovery to universities, research institutes, and pharmaceutical companies across 125 countries.
- Ownership category
- akta.pro rank
Biomatters industry classification
Industry- Product category
- Bioinformatics Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)
Keywords
Where Biomatters is headquartered
LocationHeadquarters
- HQ city
- Auckland
- HQ country
- New Zealand
- HQ region
- Oceania
Offices1 record
Markets served
Biomatters business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Geneious Prime Subscription: Comprehensive bioinformatics software subscription with annual and multi-year licensing options for molecular biology and sequence analysis tools
- Geneious Biologics Subscription: Cloud-based antibody discovery platform subscription for pharmaceutical and biotech companies
- Enterprise Licenses: Enterprise-level site licenses and quote-based pricing for large organizations including pharmaceutical companies and research institutions
- Plugins and Extensions: Additional plugins and extensions available for purchase to extend functionality
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Geneious Prime - Subscription-based licensing |
| Subscription | Annual | Geneious Biologics - Cloud platform subscription |
| Freemium | Monthly | Free Trial Available |
| Subscription | Multi-year contract | Enterprise Site Licenses |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
Biomatters product offering
Product offeringCore offering
Biomatters develops and sells Geneious, a suite of bioinformatics software used by scientists to analyze DNA and molecular sequence data. Its primary products are Geneious Prime, a comprehensive desktop suite for molecular biology and sequence analysis (including Sanger/NGS analysis, cloning, primer design, CRISPR, phylogenetics, and workflows), and Geneious Biologics, a cloud-based platform for antibody discovery, NGS screening, clustering, and candidate selection. Biomatters also offers a free tier, Geneious Biologics Starter, for basic antibody annotation.
Product overview
Geneious, a company founded in 2003 and headquartered in New Zealand, offers a portfolio of bioinformatics software solutions. The primary offerings are Geneious Prime (a comprehensive desktop-based molecular biology and sequence analysis suite) and Geneious Biologics (a cloud-based antibody discovery and screening platform), with a free tier called Geneious Biologics Starter. In 2022, Geneious became part of Dotmatics, connecting it to a broader scientific R&D software ecosystem that includes Luma (an AI-powered antibody discovery platform), GraphPad Prism, SnapGene, OMIQ, and Protein Metrics. Geneious software serves over 4,000 universities, research institutes, and businesses across 125 countries.
Differentiator
Problem solved
Functional benefit
Brands
- Geneious Prime: Comprehensive suite of molecular biology and sequence analysis tools
- Geneious Biologics
- Geneious Biologics Starter (Free)
Products and services
- Geneious Prime
Quantifiable outcome
- Used by 4,000+ universities, research institutes and businesses worldwide
- +2 more outcomes
Companies that use Biomatters
Customer profileNamed customers11 records
Segments3 records
Ideal customer profiles3 records
Biomatters technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Feature10 records
Biomatters partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- DotmaticscoreIn 2022, Geneious became part of Dotmatics, the world's largest and most powerful scientific R&D software platform. This acquisition integrated Geneious into a comprehensive portfolio combining an open data informatics framework with best-in-breed applications including GraphPad Prism, SnapGene, OMIQ, and Protein Metrics, offering end-to-end solutions for biology, chemistry, formulations, data management, flow cytometry, and more.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Biomatters competitors and assessment
Company assessmentDirect peers
- Benchling: Benchling is a cloud-native R&D platform for biology that competes directly with Geneious Prime by offering sequence design, molecular biology workflows, and a full lab notebook. Its modern cloud architecture and enterprise focus put it in direct competition for biotech and pharma R&D software budgets.
- SnapGene: SnapGene provides DNA sequence analysis, cloning, and primer design tools and is also part of the Dotmatics portfolio. Its overlapping features with Geneious Prime for in-silico cloning and sequence visualization make it a closest-in-class direct peer under the same corporate umbrella.
- Partek Incorporated: Partek provides bioinformatics software for NGS data analysis and genomics workflows. Its overlap with Geneious Prime's NGS visualization and downstream analysis capabilities makes it a direct peer in the bioinformatics software market.
- DNASTAR: DNASTAR's Lasergene suite offers DNA and protein sequence analysis, NGS assembly, and primer design. Its desktop software model and customer base in academic and pharma research make it a direct comparable to Geneious Prime.
Emerging players
- DNAnexus: DNAnexus is a cloud-based genomics data analysis and management platform used by pharma and clinical customers. It competes with Geneious for NGS analysis workloads, particularly in enterprise settings where cloud infrastructure and collaboration are priorities.
- Geneious competitors in academic molecular biology (MEGA / BioEdit / Jalview): MEGA, BioEdit, and Jalview are free, widely used academic tools for phylogenetics and sequence analysis. They compete directly with Geneious Prime's phylogenetics and alignment features and exert pricing pressure on academic licenses.
- Rosalind (Rosalind Bio): Rosalind offers a cloud-based, browser-delivered bioinformatics platform for NGS analysis and biology research. It targets similar academic and pharma customers as Geneious Prime but with a SaaS-only delivery model.
Broad incumbents
- AbCellera Biologics: AbCellera is a clinical-stage biotech and antibody discovery platform that uses high-throughput screening and AI for therapeutic antibody discovery. It is a broader incumbent comparable to Geneious Biologics in the antibody discovery and NGS screening space.
- QIAGEN Digital Insights (CLC bio): QIAGEN's CLC Genomics Workbench is a long-established bioinformatics suite for NGS analysis, sequence assembly, and phylogenetics. As a broader life sciences tools incumbent, QIAGEN competes with Geneious Prime across academic and pharma customers.
Others
- Dotmatics (Luma): Dotmatics is the parent platform that includes GraphPad Prism, SnapGene, OMIQ, Protein Metrics, and the Luma AI antibody discovery platform. As a sister-brand and parent, it is an ecosystem peer relevant for understanding Geneious's go-to-market context and competitive adjacencies.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key highlights6 records
Customer concentration
Biomatters social profiles
Digital presenceBiomatters financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biomatters leadership team
Management profileNumber of profiles
Profiles1 record
Biomatters funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biomatters M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biomatters
What does Biomatters do?
Biomatters develops and sells Geneious, a suite of bioinformatics software used by scientists to analyze DNA and molecular sequence data. Its primary products are Geneious Prime, a comprehensive desktop suite for molecular biology and sequence analysis (including Sanger/NGS analysis, cloning, primer design, CRISPR, phylogenetics, and workflows), and Geneious Biologics, a cloud-based platform for antibody discovery, NGS screening, clustering, and candidate selection. Biomatters also offers a free tier, Geneious Biologics Starter, for basic antibody annotation.
Is Biomatters a public or private company?
Biomatters is a private company. It is classified as corporate owned and is currently operating.
When was Biomatters founded?
Biomatters was founded in 2003. It employs 11 to 50 people.
Where is Biomatters based?
Biomatters is headquartered in Auckland, New Zealand, in the Oceania region.
How does Biomatters make money?
Four revenue lines are on record. Geneious Prime Subscription is the primary driver. The others are geneious Biologics Subscription, enterprise Licenses and plugins and Extensions.
Who are Biomatters's main competitors?
Direct peers on record are Benchling, SnapGene, Partek Incorporated and DNASTAR. Emerging players are DNAnexus, Geneious competitors in academic molecular biology (MEGA / BioEdit / Jalview) and Rosalind (Rosalind Bio). Broad incumbents are AbCellera Biologics and QIAGEN Digital Insights (CLC bio). Dotmatics (Luma) is listed as an others.
Does Biomatters have an API?
Yes. Geneious offers an API and CLI (Command Line Interface) for developers to integrate with Geneious Prime. The API enables developers to build automations and extensions for the bioinformatics software. Specific details about API type (REST, GraphQL), authentication method, rate limits, or sandbox availability are not specified in the available source content. Developer documentation is at manual.geneious.com/en/latest.
What industry is Biomatters in?
Biomatters's product category is Bioinformatics Software. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 541714 and its SIC code is 7372.